Evaluation on Inter-Assay Consistency and Inter-Reader Precision for PD-L1 Assays: Ventana SP263 and Dako 22C3 in Non-Small Cell Lung Cancer

被引：1
|
作者：
Lin, D. [1 ]
Yang, X. [1 ]
机构：
[1] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Pathol,Minist Educ, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
PD-L1; Assays; TPS; Non-Small Cell Lung Cancer;
D O I：
10.1016/j.jtho.2019.08.1663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-14
引用
收藏
页码：S774 / S774
页数：1
相关论文
共 50 条
  • [1] Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
    Fujimoto, Daichi
    Yamashita, Daisuke
    Fukuoka, Junya
    Kitamura, Yuka
    Hosoya, Kazutaka
    Kawachi, Hayato
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Date, Naoki
    Sakanoue, Ichiro
    Hamakawa, Hiroshi
    Takahashi, Yutaka
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2018, 38 (12) : 6891 - 6895
  • [2] Expression of PD-L1 on Routine Non-Small Cell Lung Carcinoma Sections: Comparative Assessment of SP263 (Ventana) and 22C3 (DAKO pharmDx)
    Quinn, A. M.
    Gosney, J.
    Bishop, P.
    Bloor, R.
    Harreld, C.
    Mcnulty, C.
    Bowden, R.
    Moss, A.
    Forrest, S.
    Montero, A.
    Chaturvedi, A.
    Joseph, L.
    Paiva-Correia, A.
    Doran, H.
    Taniere, P.
    Crosbie, P.
    Blackhall, F.
    Summers, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S761 - S763
  • [3] Inter-rater reliability of programmed death ligand 1 ( PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC)
    Williams, G. H.
    Nicholson, A. G.
    Snead, D. R. J.
    Thunnissen, E.
    Lantuejoul, S.
    Cane, P.
    Kerr, K. M.
    Loddo, M.
    Scott, M.
    Scorer, P. W.
    Barker, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Assessment of concordance among 22C3, SP263, and SP142 immunohistochemistry assay for PD-L1 expression in non-small cell lung cancer.
    Jung, Chi Young
    Kim, Eun Jin
    Sung, Woo Jung
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 41 - 42
  • [5] Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples.
    Scott, Marietta
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Barker, Craig
    Scorer, Paul
    Rebelatto, Marlon
    Al-Masri, Hytham
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [6] PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs An Interclone Evaluation by Differently Trained Pathologists
    Munari, Enrico
    Rossi, Giulio
    Zamboni, Giuseppe
    Lunardi, Gianluigi
    Marconi, Marcella
    Sommaggio, Marco
    Netto, George J.
    Hoque, Mohammad O.
    Brunelli, Matteo
    Martignoni, Guido
    Haffner, Michael C.
    Moretta, Francesca
    Pegoraro, Maria C.
    Cavazza, Alberto
    Samogin, Giuseppina
    Furlan, Vanna
    Mariotti, Francesca R.
    Vacca, Paola
    Moretta, Lorenzo
    Bogina, Giuseppe
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (10) : 1384 - 1389
  • [7] PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
    Dabbagh, Tamara Z.
    Sughayer, Maher A.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) : 462 - 466
  • [8] Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer
    Shigeta, Naoko
    Murakami, Shuji
    Yokose, Tomoyuki
    Isaka, Tetsuya
    Shinada, Kanako
    Nagashima, Takuya
    Adachi, Hiroyuki
    Shigefuku, Shunsuke
    Murakami, Kotaro
    Miura, Jun
    Kikunishi, Noritake
    Watabe, Kozue
    Saito, Haruhiro
    Ito, Hiroyuki
    THORACIC CANCER, 2024, 15 (17) : 1343 - 1349
  • [9] Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
    Sughayer, Maher A.
    Alnaimy, Farah
    Alsughayer, Anas M.
    Qamhia, Naim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 663 - 666
  • [10] External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different
    Dodson, Andrew
    Parry, Suzanne
    Lissenberg-Witte, Birgit
    Haragan, Alex
    Allen, David
    O'Grady, Anthony
    McClean, Emma
    Hughes, Jamie
    Miller, Keith
    Thunnissen, Erik
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 138 - 145
12345